Next Article in Journal
Genetic Instability and Chromatin Remodeling in Spermatids
Next Article in Special Issue
Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights
Previous Article in Journal
Highly Resolved Phylogenetic Relationships within Order Acipenseriformes According to Novel Nuclear Markers
Previous Article in Special Issue
Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessArticle
Genes 2019, 10(1), 39; https://doi.org/10.3390/genes10010039

TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy

1,2,†, 1,2,†, 1, 1, 1 and 1,2,3,*
1
Translational Medicine Program, Hospital for Sick Children Research Institute, 686 Bay Street, Toronto, ON M5G 0A4, Canada
2
Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
3
Department of Paediatrics, University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada
*
Author to whom correspondence should be addressed.
Co-first authors.
Received: 16 November 2018 / Revised: 24 December 2018 / Accepted: 3 January 2019 / Published: 11 January 2019
(This article belongs to the Special Issue Cystic Fibrosis: Therapy and Genetics)
  |  
PDF [3835 KB, uploaded 11 January 2019]
  |     |  

Abstract

Cystic fibrosis (CF) is an inherited monogenic disorder, amenable to gene-based therapies. Because CF lung disease is currently the major cause of mortality and morbidity, and the lung airway is readily accessible to gene delivery, the major CF gene therapy effort at present is directed to the lung. Although airway epithelial cells are renewed slowly, permanent gene correction through gene editing or targeting in airway stem cells is needed to perpetuate the therapeutic effect. Transcription activator-like effector nuclease (TALEN) has been utilized widely for a variety of gene editing applications. The stringent requirement for nuclease binding target sites allows for gene editing with precision. In this study, we engineered helper-dependent adenoviral (HD-Ad) vectors to deliver a pair of TALENs together with donor DNA targeting the human AAVS1 locus. With homology arms of 4 kb in length, we demonstrated precise insertion of either a LacZ reporter gene or a human cystic fibrosis transmembrane conductance regulator (CFTR) minigene (cDNA) into the target site. Using the LacZ reporter, we determined the efficiency of gene integration to be about 5%. In the CFTR vector transduced cells, we were able to detect CFTR mRNA expression using qPCR and function correction using fluorometric image plate reader (FLIPR) and iodide efflux assays. Taken together, these findings suggest a new direction for future in vitro and in vivo studies in CF gene editing. View Full-Text
Keywords: cystic fibrosis; gene therapy; site-specific gene targeting; viral vector; TALEN cystic fibrosis; gene therapy; site-specific gene targeting; viral vector; TALEN
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Xia, E.; Zhang, Y.; Cao, H.; Li, J.; Duan, R.; Hu, J. TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy. Genes 2019, 10, 39.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Genes EISSN 2073-4425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top